25
Participants
Start Date
December 2, 2013
Primary Completion Date
August 29, 2016
Study Completion Date
August 29, 2016
Regorafenib (Stivarga, BAY73-4506)
Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
Placebo
Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
Liverpool
Edegem
Leuven
East Melbourne
Malvern
Bentleigh East
Liège
New York
Berlin
Syracuse
Marseille
Córdoba
Philadelphia
Milan
Milan
Milan
Brescia
Oldenburg
Duke University Medical Center, Durham
Madrid
Madrid
Madrid
Brest
Bordeaux
Udine
Tours
Chattanooga
Germantown
Reggio Emilia
Valencia
Valencia
Detroit
Florence
Ramat Gan
Mainz
Rochester
Pisa
Frankfurt am Main
Clermont-Ferrand
Tel Aviv
Omaha
Lyon
New Orleans
Foggia
Dallas
Paris
Napoli
München
Poitiers
Los Angeles
Los Angeles
Los Angeles
Laguna Hills
Villejuif
Kirkland
Seattle
Seattle
Beijing
Beijing
Beijing
Beijing
Shanghai
Shanghai
Shanghai
Hangzhou
Hangzhou
Fujian Medical University Union Hospital, Fuzhou
Changsha
Wuhan
Guangzhou
Guangzhou
Kunming
Xi'an
Xi'an
Haifa
New Haven
Baltimore
New Brunswick
Buffalo
Richmond
Belo Horizonte
Porto Alegre
São José do Rio Preto
Harbin
São Paulo
Edmonton
Toronto
Sherbrooke
Montreal
Rome
Kashiwa
Sapporo
Sapporo
Sapporo
Akashi
Amagasaki
Kobe
Kasama
Yokohama
Suita
Takatsuki
Sunto
Shimotsuke
Koto-ku
Minato-ku
Mitaka
Shinagawa
Shinjuku-ku
Fukuoka
Fukuoka
Fukuoka
Almada
Porto
Santa Maria da Feira
Alicante
Badajoz
Barcelona
Royal Marsden NHS Trust (Surrey), Sutton
Bristol
London
London
Lead Sponsor
Bayer
INDUSTRY